Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.55 |
| ▸ | ANPEP | P15144 | 2/20 | 0.51 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.51 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039933 | 1.00 | MTNR1A (0.55) | MTNR1AMTNR1BANPEPRNPEPDNPEP | |
| SCHEMBL7277645 | 0.85 | MTNR1A (0.55) | MTNR1AMTNR1BANPEPRNPEPDNPEP | |
| SCHEMBL7428008 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BANPEPRNPEPDNPEP | |
| SCHEMBL6692780 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BANPEPRNPEPDNPEP | |
| SCHEMBL3662060 | 0.79 | CYP1A2 (0.55) | CYP1A2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL2846532 | 0.79 | CYP1A2 (0.55) | CYP1A2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL5052372 | 0.78 | CYP1A2 (0.68) | CYP1A2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL3056982 | 0.77 | EPHX2 (0.62) | — | |
| SCHEMBL3055746 | 0.77 | EPHX2 (0.62) | — | |
| SCHEMBL3044591 | 0.77 | CYP1A2 (0.57) | ANPEPCYP1A2EPHX1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | MTNR1A 1024/4885MTNR1B 533/4885ANPEP 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.